These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 10556107)

  • 1. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
    Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
    Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
    Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT.
    Dirksen A; Friis M; Olesen KP; Skovgaard LT; Sørensen K
    Acta Radiol; 1997 Sep; 38(5):826-32. PubMed ID: 9332238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
    Balbi B; Ferrarotti I; Miravitlles M
    Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
    [No Abstract]   [Full Text] [Related]  

  • 5. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
    Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
    Wencker M; Fuhrmann B; Banik N; Konietzko N;
    Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
    Tortorici MA; Rogers JA; Vit O; Bexon M; Sandhaus RA; Burdon J; Chorostowska-Wynimko J; Thompson P; Stocks J; McElvaney NG; Chapman KR; Edelman JM
    Br J Clin Pharmacol; 2017 Nov; 83(11):2386-2397. PubMed ID: 28662542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
    Abboud RT; Ford GT; Chapman KR
    Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.
    Dirksen A; Piitulainen E; Parr DG; Deng C; Wencker M; Shaker SB; Stockley RA
    Eur Respir J; 2009 Jun; 33(6):1345-53. PubMed ID: 19196813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
    Sclar DA; Evans MA; Robison LM; Skaer TL
    Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
    Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
    Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography.
    Shaker SB; Dirksen A; Ulrik CS; Hestad M; Stavngaard T; Laursen LC; Maltbaek N; Clementsen P; Skjaerbaek N; Nielsen L; Stoel B; Skovgaard LT; Tonnesen P
    COPD; 2009 Apr; 6(2):104-11. PubMed ID: 19378223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-1-antitrypsin replacement therapy: current status.
    Abusriwil H; Stockley RA
    Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.
    Parr DG; Dirksen A; Piitulainen E; Deng C; Wencker M; Stockley RA
    Respir Res; 2009 Aug; 10(1):75. PubMed ID: 19678952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
    Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
    Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary
    Lessard E; Young HM; Bhalla A; Pike D; Sheikh K; McCormack DG; Ouriadov A; Parraga G
    Acad Radiol; 2017 Nov; 24(11):1402-1411. PubMed ID: 28645458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
    Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.
    Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
    Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.
    Dowson LJ; Guest PJ; Stockley RA
    Am J Respir Crit Care Med; 2001 Nov; 164(10 Pt 1):1805-9. PubMed ID: 11734427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.